Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

NCT02229396 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

695

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus

Interventions

DRUG: Exantide with Dapagliflozin
DRUG: Exentide
DRUG: Dapagliflozin

Sponsor

AstraZeneca